---
title: "Understanding the Market | JACOBIO-B rose over 7% during the session as the company divests non-core projects to focus on its core pipeline of innovative oncology drugs"
description: "JACOBIO-B rose over 7% during the trading session, and as of the time of writing, it is up 6.12%, priced at HKD 7.8, with a transaction volume of HKD 23.9374 million. In terms of news, JACOBIO previou"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261807161.md"
published_at: "2025-10-20T03:54:05.000Z"
---

# Understanding the Market | JACOBIO-B rose over 7% during the session as the company divests non-core projects to focus on its core pipeline of innovative oncology drugs

> JACOBIO-B rose over 7% during the trading session, and as of the time of writing, it is up 6.12%, priced at HKD 7.8, with a transaction volume of HKD 23.9374 million. In terms of news, JACOBIO previously announced that it has signed a capital increase and equity transfer agreement with Haisong Capital and an industrial partner. According to this agreement, Haisong Capital will acquire 80% of the equity of JACOBIO's subsidiary, JACOREKANG, with an initial payment of RMB 125 million and a milestone payment of RMB 75 million. After completion, JACOBIO's stake in JACOREKANG will be reduced to 10%. The announcement stated that this transaction aligns with the group's strategic development focused on key pipeline products in oncology targeting different critical cellular pathways (including KRAS, MYC, P53, and tumor immunity), optimizing capital allocation, fully ensuring the development of core oncology pipeline projects, achieving strategic focus, enhancing organizational efficiency, while retaining future project value through a risk-sharing model. The consideration for the equity transfer (after deducting various taxes and fees) is intended to be used for the research and development, production, and commercialization of the company's Pan-KRAS inhibitors and other innovative oncology projects

According to Zhitong Finance APP, JACOBIO-B (01167) rose over 7% during the trading session, and as of the time of writing, it was up 6.12%, priced at HKD 7.8, with a transaction volume of HKD 23.9374 million.

In terms of news, JACOBIO previously announced that it had signed a capital increase and equity transfer agreement with Haisong Capital and an industrial partner. According to this agreement, Haisong Capital will acquire 80% of the equity of JACOBIO's subsidiary, JACOREKANG, with an initial payment of RMB 125 million and a milestone payment of RMB 75 million. After completion, JACOBIO's shareholding in JACOREKANG will be reduced to 10%.

The announcement stated that the transaction aligns with the group's strategic development focused on key pipeline products in oncology targeting different critical cell pathways (including KRAS, MYC, P53, and tumor immunity), optimizing capital allocation, fully ensuring the development of core oncology pipeline, achieving strategic focus, enhancing organizational efficiency, while retaining future project value through a risk-sharing model. The consideration for the equity transfer (after deducting various taxes and fees) is intended for the research and development, production, and commercialization of the company's Pan-KRAS inhibitors and other innovative oncology projects

### Related Stocks

- [01167.HK - JACOBIO-B](https://longbridge.com/en/quote/01167.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Jacobio Pharmaceuticals Partners with AstraZeneca on Pan-KRAS Inhibitor JAB-23E73 | Jacobio Pharmaceuticals has entered a licence and collaboration agreement with AstraZeneca for the pan-KRAS inhibitor JA | [Link](https://longbridge.com/en/news/270403733.md) |
| Jacobio Pharmaceuticals Unveils Promising Preclinical Data for Pan-KRAS Inhibitor | Jacobio Pharmaceuticals Group Co., Ltd. (HK:1167) presented promising preclinical data for its pan-KRAS inhibitor, JAB-2 | [Link](https://longbridge.com/en/news/262504988.md) |
| Maine CDC reports 4 additional cases of measles have been confirmed in Maine | Maine CDC reports 4 additional cases of measles have been confirmed in Maine | [Link](https://longbridge.com/en/news/276164223.md) |
| 11:53 ETVerana Health Introduces Industry First End-to-End Urologic-Oncology Datasets to Support Research | Verana Health has launched new urologic-oncology datasets aimed at enhancing research for bladder and prostate cancer tr | [Link](https://longbridge.com/en/news/276359690.md) |
| 08:46 ETCenter for Asbestos Related Disease, Inc. (CARD) Invites Community Members to Attend an Open House and Ribbon Cutting Celebration | The Center for Asbestos Related Disease, Inc. (CARD) is hosting an Open House and Ribbon Cutting celebration on February | [Link](https://longbridge.com/en/news/276235741.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.